Healthcare -
Biotechnology - NASDAQ - US
$ 10.64
-7.07 %
$ 7.17 M
Market Cap
-0.08
P/E
INCOME STATEMENT
EFFICIENCY
Earnings Waterfall
Jaguar Health, Inc.
| Revenue | 11.7 M |
| Cost Of Revenue | 1.96 M |
| Gross Profit | 9.73 M |
| Operating Expenses | 40.6 M |
| Operating Income | -30.8 M |
| Other Expenses | 8.2 M |
| Net Income | -39 M |
Income Statement
Millions
| Dec-2024 | Dec-2023 | Dec-2022 | Dec-2021 | Dec-2020 | Dec-2019 | Dec-2018 | Dec-2017 | Dec-2016 | Dec-2015 | Dec-2014 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| REVENUE | |||||||||||
| Revenue | 11.7 | 9.8 | 12.0 | 4.3 | 9.4 | 5.8 | 4.4 | 4.4 | 0.1 | 0.3 | 0 |
| GROSS PROFIT | |||||||||||
| Cost Of Revenue | 2.0 | 2.0 | 2.0 | 2.3 | 3.3 | 3.8 | 2.8 | 0.9 | 52 K | 0.1 | 0 |
| Gross Profit | 9.7 | 7.7 | 9.9 | 2.0 | 6.1 | 2.0 | 1.7 | 3.5 | 89.6 K | 0.1 | 0 |
| OPERATING INCOME | |||||||||||
| Operating Expenses | 40.6 | 42.0 | 44.4 | 41.1 | 27.4 | 26.9 | 27.3 | 18.6 | 13.7 | 12.6 | 8.3 |
| Selling, General and Administrative Expenses | 24.0 | 23.0 | 26.7 | 26.0 | 21.0 | 20.4 | 22.1 | 14.3 | 6.5 | 6.1 | 4.1 |
| Research and Development Expenses | 16.5 | 18.6 | 17.6 | 15.1 | 6.4 | 5.8 | 5.2 | 4.3 | 7.2 | 6.5 | 4.2 |
| Operating Income | (30.8) | (34.3) | (34.4) | (39.1) | (21.3) | (24.9) | (30.8) | (34.2) | (13.6) | (12.4) | (8.3) |
| PRE-TAX INCOME | |||||||||||
| Interest Income Expense | 0.2 | 6.4 | 12.7 | 8.4 | 2.8 | 5.7 | 2.6 | 1.2 | 1.0 | 3.3 | 0 |
| Total Other Income | (8.4) | (7.6) | (14.0) | (11.9) | (7.2) | (9.6) | (1.3) | (0.9) | (1.1) | (3.8) | (0.3) |
| Pre-Tax Income | (39.3) | (41.9) | (48.4) | (52.6) | (33.8) | (38.5) | (32.1) | (35.1) | (14.7) | (16.3) | (8.6) |
| NET INCOME | |||||||||||
| Tax Provision | (0.8) | 0 | (0.9) | 7.7 | 3.0 | 10 K | (1.3) | (13.2) | 1.1 | 3.8 | 0.3 |
| Net Income | (38.5) | (41.3) | (47.5) | (60.3) | (36.8) | (38.5) | (32.1) | (22.0) | (14.7) | (16.3) | (8.6) |
| EPS | 131 | 2.68 K | (4.1) | (11.4) | (72.3) | (589.4) | (366 353.3) | (9 658 965.5) | (88 496 325.2) | (169 803 473.2) | (72 643 288.7) |